# The influence of adrenoceptor blocker treatment on fracture healing in osteoporotic and non-osteoporotic bone

**Authors:** Sandra Dieterich, Christoph Kölbl, Miriam Eva Angelica Tschaffon-Müller, Oliver Küppers, Dorothea Gebauer, Melanie Rebecca Kuhn, Katarina Teresa Acker, Anita Ignatius, Melanie Haffner-Luntzer

PMC · DOI: 10.3389/fphys.2025.1726583 · Frontiers in Physiology · 2026-02-16

## TL;DR

This study examines how blocking adrenoceptors affects fracture healing in both osteoporotic and non-osteoporotic female mice, finding no improvement in healing and a sex-dependent immune response.

## Contribution

The study reveals a sex-dependent effect of adrenoceptor blocker treatment on immune response and fracture healing in female mice.

## Key findings

- Blocking adrenoceptors early in fracture healing did not improve healing in osteoporotic or non-osteoporotic mice.
- Beta blockade increased neutrophil numbers in non-osteoporotic female mice, suggesting an elevated immune response.
- Results indicate a sex-dependent effect of adrenoceptor blocker treatment on fracture healing outcomes.

## Abstract

Fracture healing is a highly dynamic process that involves inflammation, cell recruitment, angiogenesis, and subsequent bone formation and remodeling. Increasing evidence suggests the pivotal role of adrenergic signaling in musculoskeletal repair and bone-related diseases such as osteoporosis. Furthermore, impaired fracture healing in osteoporotic female mice might be attributed to an overshooting immune response with increasing numbers of neutrophils found in the early fracture hematoma. Earlier studies showed that an unspecific blockade of the β-adrenoceptor with propranolol reduces the number of neutrophils in the fracture hematoma in male mice, which might also help alleviate the overshooting immune response in female osteoporotic mice. In this study, we hypothesized that adrenoceptor blocker treatment in the early inflammatory phase of fracture healing rescues the excessive immune response in osteoporotic female mice and thereby improves fracture healing. However, our results indicate that an early blockade of adrenergic receptors does not improve fracture healing in osteoporotic and non-osteoporotic mice. In contrast to earlier studies with male mice, beta blockade (propranolol and butoxamine) in female non-osteoporotic mice increased the number of neutrophils in the early fracture hematoma, indicating an elevated immune response and a sex-dependent effect of adrenoceptor blocker treatment.

## Linked entities

- **Chemicals:** propranolol (PubChem CID 4946), butoxamine (PubChem CID 18026)
- **Diseases:** osteoporosis (MONDO:0005298)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Csf1 (colony stimulating factor 1 (macrophage)) [NCBI Gene 12977] {aka BAP025, Csfm, MCSF, Mhdabap25, PG-M-CSF, op}, Il22 (interleukin 22) [NCBI Gene 50929] {aka IL-22, IL-22a, ILTIFa, If2b1, Iltif}, Lif (leukemia inhibitory factor) [NCBI Gene 16878], Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, Il33 (interleukin 33) [NCBI Gene 77125] {aka 9230117N10Rik, Il-33, Il1f11, NF-HEV}, Cxcl2 (C-X-C motif chemokine ligand 2) [NCBI Gene 20310] {aka CINC-2a, GROb, Gro2, MIP-2, MIP-2a, Mgsa-b}, Cd19 (CD19 antigen) [NCBI Gene 12478], Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, Igh-V7183 (immunoglobulin heavy chain (V7183 family)) [NCBI Gene 16059] {aka B9-scFv, IgG, IgH, IgVH1(VSG), VH7183, VI24H}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}, Adra1d (adrenergic receptor, alpha 1d) [NCBI Gene 11550] {aka Adra-1, Adra1, Adra1a, Gpcr8, Spr8, [a]1d}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il23a (interleukin 23, alpha subunit p19) [NCBI Gene 83430] {aka IL-23, p19}, Gpr34 (G protein-coupled receptor 34) [NCBI Gene 23890] {aka Lypsr1}, Ccl11 (C-C motif chemokine ligand 11) [NCBI Gene 20292] {aka Scya11, eotaxin}, Acp5 (acid phosphatase 5, tartrate resistant) [NCBI Gene 11433] {aka TRACP, TRAP}, Cxcl5 (C-X-C motif chemokine ligand 5) [NCBI Gene 20311] {aka AMCF-II, Cxcl6, ENA-78, GCP-2, LIX, Scyb5}, Il7 (interleukin 7) [NCBI Gene 16196] {aka A630026I06Rik, Il-7, hlb368}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Il31 (interleukin 31) [NCBI Gene 76399] {aka 1700013B14Rik}, Il3 (interleukin 3) [NCBI Gene 16187] {aka BPA, Csfmu, HCGF, Il-3, MCGF, PSF}, Btc (betacellulin, epidermal growth factor family member) [NCBI Gene 12223] {aka Bcn}, Pth (parathyroid hormone) [NCBI Gene 19226] {aka Pthp}, Il9 (interleukin 9) [NCBI Gene 16198] {aka Il-9, P40}, Il1rl1 (interleukin 1 receptor-like 1) [NCBI Gene 17082] {aka DER4, Fit-1, Ly84, ST2L, St2, St2-rs1}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Adrb2 (adrenergic receptor, beta 2) [NCBI Gene 11555] {aka Adrb-2, Badm, Gpcr7}, Ccl7 (C-C motif chemokine ligand 7) [NCBI Gene 20306] {aka MCP-3, Scya7, fic, marc, mcp3}, Il25 (interleukin 25) [NCBI Gene 140806] {aka IL-17e, IL-25, Il17e}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Ccl3 (C-C motif chemokine ligand 3) [NCBI Gene 20302] {aka G0S19-1, LD78alpha, MIP-1alpha, MIP1-(a), MIP1-alpha, Mip1a}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Csf3 (colony stimulating factor 3 (granulocyte)) [NCBI Gene 12985] {aka Csfg, G-CSF, MGI-IG}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Il5 (interleukin 5) [NCBI Gene 16191] {aka Il-5}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, Klra1 (killer cell lectin-like receptor, subfamily A, member 1) [NCBI Gene 16627] {aka A1, CH29-493D4.3, Klra22, Ly49a, Ly49o<129>, Ly49v}, Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, Ifnl3 (interferon lambda 3) [NCBI Gene 338374] {aka IFL-1, IL-28B, INF-alpha, INF-lambda, If1ia2, Il28}, Il15 (interleukin 15) [NCBI Gene 16168] {aka IL-15}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Il19 (interleukin 19) [NCBI Gene 329244], Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Il27 (interleukin 27) [NCBI Gene 246779] {aka IL-27, IL-27-A, IL-27p28, IL27-A, Il30, p28}, Tnfsf13b (tumor necrosis factor (ligand) superfamily, member 13b) [NCBI Gene 24099] {aka BAFF, BLyS, D8Ertd387e, TALL-1, TALL1, THANK}, Il7r (interleukin 7 receptor) [NCBI Gene 16197] {aka CD127, IL-7Ralpha}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Il2ra (interleukin 2 receptor, alpha chain) [NCBI Gene 16184] {aka CD25, Il2r, Ly-43}, Cd8a (CD8 subunit alpha) [NCBI Gene 12525] {aka Ly-2, Ly-35, Ly-B, Lyt-2}, Ighv1-9 (immunoglobulin heavy variable 1-9) [NCBI Gene 668478] {aka Gm16697, Igg2a}, Bdkrb2 (bradykinin receptor, beta 2) [NCBI Gene 12062] {aka B(2), B2, B2R, BK-2, BK2, BK2R}
- **Diseases:** bone loss (MESH:D001847), Osteoporosis (MESH:D010024), cardiovascular diseases (MESH:D002318), fractured femur (MESH:D000092524), TBI (MESH:D000070642), Osteoporotic (MESH:D058866), tumors (MESH:D009369), Bone fracture (MESH:D050723), pain (MESH:D010146), inflammation (MESH:D007249), tissue trauma (MESH:D014947), fracture hematoma (MESH:D006406), bone resorption (MESH:D001862), TMD (MESH:D001851), blood vessel damage (MESH:D009383)
- **Chemicals:** hydroxyapatite (MESH:D017886), propranolol (MESH:D011433), Catecholamine (MESH:D002395), hematoxylin (MESH:D006416), EPX480-20834- (-), Safranin O (MESH:C009195), Dopamine (MESH:D004298), paraformaldehyde (MESH:C003043), butoxamine (MESH:D002078), 7AAD (MESH:C025942), Adrenaline (MESH:D004837), FITC (MESH:D016650), N (MESH:D009584), Phentolamine (MESH:D010646), oxygen (MESH:D010100), paraffin (MESH:D010232), NaCl (MESH:D012965), Noradrenaline (MESH:D009638), biotin (MESH:D001710), progesterone (MESH:D011374), isoflurane (MESH:D007530), clindamycin (MESH:D002981)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Armenian hamster [taxon 10032], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950559/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950559/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950559/full.md

---
Source: https://tomesphere.com/paper/PMC12950559